Recent clinical trials of Novo Nordisk’s blockbuster GLP-1 drug semaglutide for Alzheimer’s disease may have failed to show ...
Investing.com -- Moody’s Ratings has affirmed Eli Lilly and Company ’s Aa3 senior unsecured notes ratings and long-term issuer rating while revising the outlook to positive from stable, the rating ...
Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...
Dec 12 (Reuters) - Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, ...
As researchers continue to advance the understanding of Alzheimer’s disease, new treatment options are offering hope for ...
Experts at a roundtable in Boston, Massachusetts, on November 3, 2025, discussed improving early Alzheimer disease diagnosis, addressing workforce and equity gaps, and expanding access to new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback